Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 13-valent conjugate vaccine (Nivad Pharmed Salamat)
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pneumovax 13 is an incorrect name or misnomer that conflates Merck's 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23) and Pfizer's 13-valent pneumococcal conjugate vaccine (Prevnar 13), or refers to PneumoConj 13, a 13-valent pneumococcal conjugate vaccine developed by NIVAD Pharmed Salamat. PneumoConj 13 consists of pneumococcal capsular polysaccharides from 13 Streptococcus pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) individually conjugated to a non-toxic diphtheria toxin mutant carrier protein (CRM197). It is designed to active immune responses for the prevention of invasive pneumococcal diseases, such as pneumonia, meningitis, and bacteremia, particularly in infants and children.
- Brand names
- PneumoConj 13PneumoConj13PneumoConj-13Pneumovax 13Pneumovax13Pneumovax-13
- Other names
- PCV13PCV-13PCV 13pneumococcal 13-valent conjugate vaccinepneumococcal13-valent conjugate vaccinepneumococcal-13-valent conjugate vaccinepneumococcal conjugate vaccine 13-valent
02
Targets
TCR-CRM197 (CRM197-specific T-cell receptor)CPS (Streptococcus pneumoniae capsular polysaccharide)BCR-PnPS (B-cell receptor specific for pneumococcal capsular polysaccharides)
Beyond the preview
Go deeper on pneumococcal 13-valent conjugate vaccine (Nivad Pharmed Salamat).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 13-valent conjugate vaccine (Nivad Pharmed Salamat).